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Objectives: Psoriasis is a papulosquamous skin disease characterized by recurring 
thick, itchy and dry red patches covered with silvery scales. It has been shown that 
patients with psoriasis have a reduction in their quality of life similar to patients 
with other chronic diseases, such as ischemic heart disease and diabetes. The objec-
tive of this study was to evaluate how health-related quality of life (HRQL) was taken 
into consideration in the evaluation of psoriasis products approved by the FDA and 
the EMA since 1995. MethOds: The websites of the FDA and the EMA were explored 
to identify all psoriasis products approved. PROLabels was used to identify products 
with a PRO claim in label. All corresponding clinical reviews (FDA), and assessments 
reports (EMA) were reviewed for HRQL evaluation. Results: Twenty-seven products 
have been approved since 1995 (18 FDA, nine EMA). Six products were common to 
both agencies (i.e., adalimumab, apremilast, etanercept, infliximab, secukinumab, 
ustekinumab). For the products approved by both agencies, the same clinical studies 
were submitted. PRO claims were found in nine products (eight EMA, one FDA). HRQL 
was mentioned in the label of all EMA products (mainly, improvement in QOL), but 
not the FDA’s. The Dermatology Life Quality Index (DLQI) was used for all products, 
and the SF-36 for six products. Among the eight EMA products with a HRQL claim, 
five products have been also approved by the FDA. In two cases (apremilast, usteki-
numab), the medical review was not available. Therefore, reasons for not including 
HRQL in the label could not be retrieved. For the three other products (adalimumab, 
infliximab, secukinumab), HRQL was not mentioned in the review. cOnclusiOns: 
The EMA seems to consider HRQL as a valuable endpoint in the evaluation of pso-
riasis products in contrast with the FDA. More harmonization between agencies 
might be beneficial to patients’ information.
PSS68
woRk PRoDuctivity anD activity iMPaiRMent aMong cHRonic 
SPontaneouS/iDioPatHic uRticaRia PatientS: ReSultSfRoM tHe fiRSt 
inteRnational buRDen of illneSS StuDy (aSSuRe-cSu)
Balp M1, Chambenoit O2, Chiva-Razavi S2, Lynde C3, Sussman G4, Chapman-Rothe N5, 
Weller K6, Maurer M6, Koenders J7, Knulst AC8, Halliday A9, Alexopoulos ST9,  
Nakonechna A10, Grattan C11, Abouzakouk M10, Sweeney C12, Radder C12, Wolin D13, 
McBride D14, Hollis K12, Tian H15, Elberink JN16
1Novartis Pharma AG, Basel, Switzerland, 2Novartis Pharmaceuticals Canada Inc., Dorval, 
QC, Canada, 3Lynderm Research Inc., Toronto, ON, Canada, 41St Michael’s Hospital, University 
of Toronto, Toronto, ON, Canada, 5Novartis Pharma GmbH, Nuernberg, Germany, 6Charite - 
Universitätsmedizin Berlin, Berlin, Germany, 7Novartis Pharma B.V., Arnhem, The Netherlands, 
8University Medical Center Utrecht, Utrecht, The Netherlands, 9Novartis Pharmaceuticals UK 
Limited, Surrey, UK, 10Hull and East Yorkshire NHS Hospital Trust, Hull, UK, 11Norfolk and 
Norwich University Hospital, Norwich, UK, 12RTI Health Solutions, Research Triangle Park, 
NC, USA, 13RTI Health Solutions, Ann Arbor, MI, USA, 14RTI Health Solutions, Manchester, UK, 
15Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 16Unviersity Medical Center 
Groningen, Groningen, The Netherlands
Objectives: The ASSURE-CSU study is an observational, non-interventional, mul-
tinational study conducted to identify and quantify the humanistic and economic 
burden of illness in inadequately controlled CSU/CIU patients. Here we summarise 
the work and activity impairment among patients enrolled in Canada, Germany, UK, 
and the Netherlands. MethOds: This study included a 1-year retrospective medical 
record abstraction, a cross-sectional patient-reported outcomes survey and a 7-day 
prospective patient diary. Adult patients with CSU/CIU inadequately controlled with 
H1-antihistamines, with disease persisting for ≥ 12 months were assessed. Patients 
completed the Work Productivity and Activity Impairment-Specific Health Problem 
(WPAI-SHP) questionnaire, and Resultswere described as mean (SD). Activity impair-
ment was assessed among all patients; only employed patients were queried about 
work impairment. Results: A total of 86, 94, 74 and 93 patients completed the 
patient diary in Canada, Germany, UK and the Netherlands, respectively. Of these, 
54.7%, 72.3%, 51.4% and 52.7% patients were currently employed, respectively. In 
the Canadian cohort, mean time loss due to absenteeism and presenteeism were 
6.0% (12.0%) and 29.8% (26.3%) with an overall work productivity impairment of 
30.6% (27.0%) and activity impairment of 38.3% (31.3%). Corresponding values for 
Germany were 7.4% (20.0%), 27.9% (25.7%), 30.5% (26.6%) and 36.4% (28.5%), respec-
tively. In UK, mean time loss due to absenteeism was 9.9% (23.2%), presenteeism 
33.1% (30.0%), overall work productivity impairment 35.3% (30.9%) and activity 
impairment 39.5% (30.3%). In the Netherlands, corresponding values were 2.3% 
(8.9%), 19.9% (25.4%), 20.7% (26.8%) and 31.0% (27.9%), respectively. The highest per-
centage of time missed due to CSU/CIU was reported in patients with moderate and 
severe CSU/CIU. cOnclusiOns: The Resultsare consistent among the countries 
and demonstrate that symptomatic patients with CSU/CIU experience a substantial 
impact on their daily activities and that many employed patients are affected at 
work by their disease.
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Patient DiagnoStic tHeRaPeutic PatHway foR PatientS witH 
PSoRiaSiS tHe oRganiSational analySiS of 13 excellence centReS of 
tHe tuScany Region (italy)
Cannizzo S, Palla   I, Turchetti G
Scuola Superiore Sant’Anna, Pisa, Italy
bAckgROund: Psoriasis is an chronic inflammatory disease of the skin affecting 
approximately 1-3% of population worldwide, almost 2% in Europe and 2.8% in 
Italy. Psoriasis has been associated with several comorbidities as arthropathy, 
permanent disfigurement), require systemic treatment. Few studies have evalu-
ated the psychosocial and quality of life impact of IH and there is currently a 
lack of data concerning the burden of disease. The present study aims to char-
acterize IH, and provide a comprehensive evaluation of the burden of disease 
on families, in Europe and in the United States. MethOds: International cross-
sectional study conducted in children newly diagnosed with IH, aged under 5 
months at diagnosis and requiring systemic treatment. The primary caregiver 
was asked to complete two self-administered questionnaires on the day of the 
consultation :the Hemangioma Family Burden (HFB) and a Family Member ques-
tionnaire Results: A total of 693 individuals participated in the study.Mean 
age ranged from 5.24 to 16.77 months with the majority of IH cases occurring 
in females. Approximately 80% of all cases were moderate or severe and the 
majority of patients (≥ 71.2%) received propranolol. Consistent across countries, 
the majority of parents (≥ 70%) reported a psychological impact resulting from 
their child’s IH but less than 10% were offered psychological support. In addi-
tion, approximately 50% of parents reported that their child’s condition affected 
their professional life. The global HFB score increased significantly (p < 0.0001) 
with increased IH severity. The majority (> 90%) of parents were satisfied with the 
care of their child and their child’s IH. cOnclusiOns: The present study, using 
the validated HFB questionnaire, provides previously unprecedented insights 
into the burden of IH, and highlights potential areas for future focus in assisting 
families.
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Objectives: Eating is a pleasure for most people in daily life. It involves not only the 
physiologic intake of nourishment but also important social, psychologic, and cul-
tural experiences. However, few studies have been assessed the impact of dysphagia 
on quality of life (QOL). Also, the association between dysphagia and perspectives of 
happiness is unknown. We aimed to examine the association between QOL and per-
spectives of happiness in middle-aged and older people with dysphagia. MethOds: 
We collected data from 138 dysphagia patients in university hospitals and clinics 
at Kyushu and Tokai area, Japan (mean age ± SD, 73 ± 11 years; range 40–98 years). 
The total of 12% in the subjects had have tube feeding. QOL was assessed using 
the dysphagia-related QOL scale which consisted of 7 domains. Happiness was 
evaluated using one item of a questionnaire. Clinical information was provided by 
medical professionals. Perspectives of happiness was categorized as “very happy,” 
“quite happy,” “neither happy/nor unhappy,” or “not at all happy.” We computed 
the mean QOL scores in each domain according to the level of happiness, adjust-
ing for age, gender and nutrient intake, by analysis of covariance. The p values for 
trend were calculated. Results: Overall, 26% reported feeling “very happy” and 
46% were “quite happy”, whereas 20% were “neither happy/nor unhappy” and 8% 
were “not at all happy.” There was no significant relationship between age, the level 
of happiness and the severity of dysphagia. The scores of “Symptom” (p= 0.04) and 
“Resignation” (p= 0.04) domains increased with decreasing the level of happiness. 
Even after statistical adjustment for activities of daily living, these associations 
remained significant. cOnclusiOns: Symptoms and resignation regarding dys-
phagia were negatively associated with happiness. The improvement of QOL may 
have the positive impact on perspectives of happiness in middle-aged and older 
people with dysphagia.
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Objectives: A 75% improvement in the Psoriasis Area and Severity Index (PASI 
75) is generally considered the clinical gold standard of treatment efficacy in 
patients with psoriasis. Outcomes for patients who achieve PASI 75 but not higher 
levels of response such as 90% or 100% PASI improvement (PASI 90 or PASI 100) 
are not fully characterized. This evaluation summarized the incremental benefits 
in outcomes such as health-related quality of life (HRQoL) of achieving complete 
or near-complete resolution of psoriasis, indicated by PASI ≥ 90 and/or Physician 
Global Assessment (PGA) score of 0, compared with lesser response. MethOds: 
A targeted literature search was conducted in the PubMed and Embase databases 
using a date limit of 10 years (January 1, 2005–March 10, 2015). Various search terms 
were used, including Medical Subject Heading (MeSH) and free-text terms. One 
reviewer performed level l screening on 328 titles and abstracts and level 2 screen-
ing on 92 full-text articles. Results: A total of 20 articles were ultimately selected 
that focused on the added value of achieving complete or near-complete resolution 
of psoriasis. Several analyses of clinical studies of adalimumab, infliximab, ixeki-
zumab, brodalumab, and mixed treatments have indicated that achieving PASI 90, 
PASI 100, and/or a PGA score of 0 yields benefits as demonstrated by significant 
improvements in patient-reported outcomes (e.g., Dermatology Life Quality Index 
score, measures of symptom severity, concomitant topical medication use) com-
pared with a lower PASI or PGA response. cOnclusiOns: This literature summary 
provides further evidence that complete or near-complete resolution in psoria-
sis is associated with better patient-reported outcomes. Accordingly, establish-
ing complete or near-complete resolution as the therapeutic goal would have a 
significant impact on HRQoL and other outcomes in patients with moderate to 
severe psoriasis.
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to understanding implications for lifecycle management. MethOds: Secondary 
research was conducted to identify approved indications and official list prices 
from the British National Formulary, the French Assurance Maladie database and 
the German Rote List for ranibizumab (Lucentis, Roche) and aflibercept (Eylea, Bayer) 
from launch to 2015. Indications were reviewed based on the EMA and individual 
countries’ official journals. Annualized treatment costs were calculated based on 
the official list prices and compared across countries and over time. Results: 
Ranibizumab was approved in 2007 for wet age-related macular degeneration 
(AMD). In 2010, 2011 and 2013, the list of indications expanded to include diabetic 
macular edema (DME), retinal vein occlusion and pathologic myopia, respectively. 
Aflibercept, another anti-VEGF treatment, gained EMA license in 2012 for wet AMD 
and for DME in 2014. Among countries, France has seen the biggest ranibizumab 
list price discount, with about 44% reduction between 2007 and 2015. In Germany, 
price of ranibizumab dropped by 15% in 2009 before aflibercept and dexametha-
sone (Ozurdex, Allergan) entered the market, and has since remained stable. Price 
of ranibizumab in the UK has remained stable since launch. Aflibercept launched 
at a 36% to 42% lower annual cost compared to ranibizumab across countries. So 
far prices remain stable. cOnclusiOns: Due to different market characteristics, 
the impact of indication expansion on price varies across the markets in scope. 
Maintaining a high list price is complicated in price regulated countries. List prices 
are not affected by subsequent indications in free pricing markets, where contract-
ing and confidential discounts are usually key for access. To maintain high list prices 
and avoid impact of international price referencing, patient access schemes may 
be potential options, but acceptability varies across countries.
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Objectives: Glaucoma is associated with elevated pressure in the eye (intraocular 
pressure) that may cause injury to the eye if not treated, and as a result, lead to 
blindness. The aim of this study was to identify the types of drug treatments that 
were used between 2013 and 2014 in Brazil. MethOds: Patients were identified 
through the health insurance database of Brazil, from January 2013 to December 
2014. The patients were selected with ICD-H40 and its subcategories and bought 
antiglaucoma drugs in the analyzed period. From the date of the purchase, it’s 
possible to obtain a methodology capable of identifying if a patient has used more 
than a drug for the treatment. It was then possible to find the main associations 
of glaucoma ophthalmic solutions. Results: From a total of 169,741 patients who 
bought some kind of antiglaucoma medication, 53,228 used more than one type 
of eye drop. The molecules analyzed were: Timolol, Dorzolamide, Brimonidine, 
Brinzolamide, Travoprost, Bimatoprost and Latanoprost. Since Timolol was the 
most representative drug of this period on purchases and was present in 36.7 % of 
the total purchases, with or without association with another molecule, it has been 
selected the three most representative associations in the sample under study. It 
has been found that Timolol associated with Dorzolamide corresponded to 22.8 % 
of the procurement, followed by associations between Timolol and Brimonidine 
(21.2 %) and Brinzolamide and Timolol (11.2%). cOnclusiOns: Approximately 40% 
of the patients in supplementary health sample from Brazil make use of more 
than one drug for Glaucoma treatment, this fact confirms the protocol realized 
by Brazil’s Health Ministry, where it is described that the therapeutic class, block 
beta-receptor, is the main class for treat Glaucoma and it is usually combined with 
another antiglaucoma class to reduce the intraocular pressure.
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Objectives: Diabetic Macular Edema (DME) is a leading cause of vision loss and 
blindness. The aim of the study is the evaluation of the benefits concerning the intro-
duction of an additional alternative technology, Dexamethasone intravitreal implant 
(DEX), in comparison with the present scenario consisting of the repeated adminis-
tration of intravitreal injections of Ranibizumab. They differ for the number of injec-
tions and adverse events (AEs) occurring after each therapeutic cycle. MethOds: An 
HTA was conducted within 3 Italian Departments of Ophthalmology, in Lombardy 
Region. Qualitative and quantitative data were collected using specific validated 
questionnaires and self-reported interviews, applying a MCDA approach and con-
sidering 7 dimensions resulting from the EUnetHTA Core Model. Results: At the 36 
month time point of the base-case scenario for market penetration, the introduction 
of DEX could lead to i) significant economic savings to the Regional Health Service 
(-15%), even considering the AEs impacts (14.82% severe AEs for Ranibizumab vs 
27.46% mild and moderate AEs for DEX); ii) an optimization of the operating theatre’s 
time, with fewer minutes spent delivering an entire treatment cycle (-27%); iii) a 
perception of improved staff workflow organization (+209%); iv) a decrease of social 
expenditure, in terms of productivity loss, with both transportation and waiting 
time’s reduced (-69%); v)an improvement on equity aspects, considering in particular 
advantages in caregivers’ quality of life (233%), since new treatment requires fewer 
injections. cOnclusiOns: The Resultssuggest that DEX could be considered an 
advantageous technological alternative to adopt within the DME target population. 
It acquired a higher score than the comparator (0.579 vs 0.472, considering the final 
normalized weight derived from the MCDA approach). Economic, organizational and 
equity savings could be reinvested within the same therapeutic area, i) improving 
patient access and adherence to therapy, ii) treating a wider population, iii) reducing 
waiting lists.
inflammatory bowel diseases, eye diseases, metabolic diseases and psychological 
disorders. Objectives: The main objective of the study is to design an optimized 
Patient Diagnostic Therapeutic Pathway for the Tuscany Region (Italy) character-
ized by higher quality of care and higher levels of organizational and economic 
efficiency. MethOds: Research and analysis of the scientific literature and of the 
clinical guidelines on the main dimensions of psoriasis and patient care. Design 
of ad hoc questionnaire useful to collect data and information regarding both the 
organizational structure of the 13 Centers and the different phases of patients 
pathways. Conduction of semi-structured interviews to the clinicians. Realization 
of 13 flow charts representing the patients pathways, from the pre-diagnosis phase 
to the follow-up phase. Results: The analysis shows similarities between the 
Centers in the phases of treatment and follow-up, principally due to their clinical 
nature. Major organizational differences have been recorded in the pre- diagnosis 
and the diagnosis phases due to dissimilar modalities of enrolment of patients. 
The analysis of the thirteen patients pathways has allowed the identification of 
an unique optimized pathway with improved characteristics for the patient. The 
diffusion of the optimized pathway will favour the adoption of a virtuous cycle of 
dialogue between the professionals and the progressive “homogenization” of some 
phases of the hospital management of the patient with psoriasis. cOnclusiOns: 
The study identifies an optimized pathway - able to engage all the clinicians 
involved in the care of the patient and his/her comorbidities - to be adopted at 
the regional level for a more effective, more integrated and efficient management 
of psoriasis.
PSS70
Real-woRlD tReatMent PatteRnS of RanibizuMab aMong PatientS 
witH Retinal DiSeaSeS in canaDa: 5 yeaRS of Data
Rousseau C, Saad R, Davies B, Zaour N
Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada
Objectives: To assess the annual frequency of injections of ranibizumab over 
time for the treatment of retinal diseases in Canada. MethOds: The Rx Dynamics 
database (IMS Health Canada Inc.) for the Ontario Public Drug Program (OPDP), the 
Régie de l’assurance-maladie du Québec (RAMQ) and the national Private Drug Plan 
(PDP) was used for the period ranging from January 2008 to January 2015 to track 
the mean number of claims per year per patient. Longitudinal and cross-sectional 
analyses were performed. Analyses were also performed by indication (wAMD, DME 
and RVO) when the information was available. The index date was defined as the 
date of the first ranibizumab claim. Patients with no active claim of ranibizumab 
during a specific year were not included in the mean of that year. One claim equals 
one injection. Results: For the longitudinal analyses, where the three cohorts of 
patients were followed for 5 consecutive years, the mean number of injections are 
5.9, 5.5, 5.6, 5.7 and 5.9 for the OPDP cohort (n= 12,944), 5.2, 4.7, 5.5, 5.9 and 5.8 for 
the RAMQ cohort (n= 1,835) and 4.2, 5.1, 5.0, 5.4 and 5.1 for PDP (n= 449) cohort. For 
the cross-sectional analyses, the mean number of injections for the first year of 
treatment are 5.9 for the OPDP (n= 60,105), 5.9 for RAMQ (n= 11,557) and 5.1 for PDP 
(n= 5,292). In addition, similar Resultsare obtained when the mean number of injec-
tions is assessed by retinal conditions. cOnclusiOns: These Resultssuggest that 
Canadian patients treated with ranibizumab receive a mean number of injections 
of 5-6 per year over time. These Resultsalso confirm the uptake of individualized 
treatment regimen, such as treat and extend, by the Canadian physicians. All find-
ings and Conclusionsare those of the author, and are based in part on data licensed 
from IMS Health Canada Inc. (all rights reserved).
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Objectives: Targeted therapies have been used and reimbursed for treatment of 
eye malignancies by Taiwan National Health Insurance in the past few years. This 
study examined the recent trend in use and costs of antineoplastic agents for treat-
ment of eye malignancies in Taiwan from 2009 to 2012. We also forecasted use and 
costs of targeted therapies up to and including year 2016 based on the current 
patterns. MethOds: The monthly claims data for eye malignancy-related anti-
neoplastic agents were retrieved from Taiwan’s National Health Insurance Research 
Database (2009-2012). We calculated the number of prescriptions and costs for each 
class of medications, and analyzed their time trends. In addition, using a time series 
design with ARIMA models, we estimated the market share by prescription volume 
and the proportion of costs for targeted therapies for years 2015 and 2016. Results: 
The market share of targeted therapies grew from 1.56% in 2009 to 9.98% in 2012 
among all antineoplastic agents, and the proportion of costs for targeted therapies 
rose from 15.12% in 2009 to 58.88% in 2012. Especially, the proportion of costs for pro-
tein kinase inhibitors grew from 25.62% to 45.28% among all antineoplastic agents 
between 2010 and 2012. The market share and the proportion of costs for targeted 
therapies were predicted to reach 27.33% and 91.39% by the fourth quarter in 2016 
respectively. cOnclusiOns: This is the first study that examined and forecasted 
the use of targeted therapies for treatment of eye malignancies in Taiwan. Our 
findings indicate that, compared with other classes of drugs, targeted therapies 
are becoming the main treatments for eye malignancy in Taiwan, and due to their 
high costs they are likely to cause great economic burden.
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Objectives: To analyze the impact of indication expansion and market competition 
on anti-VEGF drug prices in the United Kingdom, France and Germany, with a view 
